Top

Published in:

01-12-2020 | Tuberculosis | Research article

Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence

Authors: Jacques L. Tamuzi, Birhanu T. Ayele, Constance S. Shumba, Olatunji O. Adetokunboh, Jeannine Uwimana-Nicol, Zelalem T. Haile, Joseph Inugu, Peter S. Nyasulu

Published in: BMC Infectious Diseases | Issue 1/2020

Abstract

Background

The triple burden of COVID-19, tuberculosis and human immunodeficiency virus is one of the major global health challenges of the twenty-first century. In high burden HIV/TB countries, the spread of COVID-19 among people living with HIV is a well-founded concern. A thorough understanding of HIV/TB and COVID-19 pandemics is important as the three diseases interact. This may clarify HIV/TB/COVID-19 as a newly related field. However, several gaps remain in the knowledge of the burden of COVID-19 on patients with TB and HIV. This study was conducted to review different studies on SARS-CoV, MERS-CoV or COVID-19 associated with HIV/TB co-infection or only TB, to understand the interactions between HIV, TB and COVID-19 and its implications on the burden of the COVID-19 among HIV/TB co-infected or TB patients, screening algorithm and clinical management.

Methods

We conducted an electronic search of potentially eligible studies published in English in the Cochrane Controlled Register of Trials, PubMed, Medrxiv, Google scholar and Clinical Trials Registry databases. We included case studies, case series and observational studies published between January, 2002 and July, 2020 in which SARS-CoV, MERS-CoV and COVID-19 co-infected to HIV/TB or TB in adults. We screened titles, abstracts and full articles for eligibility. Descriptive and meta-analysis were done and results have been presented in graphs and tables.

Results

After removing 95 duplicates, 58 out of 437 articles were assessed for eligibility, of which 14 studies were included for descriptive analysis and seven studies were included in the meta-analysis. Compared to the descriptive analysis, the meta-analysis showed strong evidence that current TB exposure was high-risk COVID-19 group (OR 1.67, 95% CI 1.06–2.65, P = 0.03). The pooled of COVID-19/TB severity rate increased from OR 4.50 (95% CI 1.12–18.10, P = 0.03), the recovery rate was high among COVID-19 compared to COVID-19/TB irrespective of HIV status (OR 2.23, 95% CI 1.83–2.74, P < 0.001) and the mortality was reduced among non-TB group (P < 0.001).

Conclusion

In summary, TB was a risk factor for COVID-19 both in terms of severity and mortality irrespective of HIV status. Structured diagnostic algorithms and clinical management are suggested to improve COVID-19/HIV/TB or COVID-19/TB co-infections outcomes.

Available only for authorised users

Soriano V, Barreiro P. Impact of new coronavirus epidemics on HIV-infected patients. AIDS Rev. 2020;22(1):57–8.PubMedCrossRef

Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–32.PubMedPubMedCentralCrossRef

Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–92.CrossRefPubMed

Lipsitch M, Cohen T, Cooper B, Robins JM, Ma S, James L, et al. Transmission dynamics and control of severe acute respiratory syndrome. Science (New York, NY). 2003;300(5627):1966–70.CrossRef

Wallinga J, Teunis P. Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. Am J Epidemiol. 2004;160(6):509–16.PubMedCrossRef

Lin Q, Chiu AP, Zhao S, He D. Modeling the spread of Middle East respiratory syndrome coronavirus in Saudi Arabia. Stat Methods Med Res. 2018;27(7):1968–78.PubMedCrossRef

World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 197 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200804-covid-19-sitrep-197.pdf?sfvrsn=94f7a01d_2. Accessed 05 Aug 2020.

Swaminathan S, Nagendran G. HIV and tuberculosis in India. J Biosci. 2008;33(4):527–37.PubMedCrossRef

UNAIDS. Global HIV & AIDS statistics — 2019 fact sheet. 2019. https://www.unaids.org/en/resources/fact-sheet. Accessed 07 May 2020.

10.

World Health Organization. TB/HIV FACTS 2009. 2009. https://www.who.int/tb/challenges/hiv/factsheet_hivtb_2009update.pdf. Accessed 07 May 2020.

11.

Dirlikov E, Raviglione M, Scano F. Global tuberculosis control: toward the 2015 targets and beyond. Ann Intern Med. 2015;163(1):52–8.PubMedCrossRef

12.

U.S. Agency for International Development. USAID Report on the twin epidemics: HIV AND TB Co-infection. 2014. https://www.usaid.gov/news-information/fact-sheets/twin-epidemics-hiv-and-TB-co-infection. Accessed 07 May 2020.

13.

Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS (London, England). 2015;29(15):1987–2002.CrossRef

14.

Jiang H, Zhou Y, Tang W. Maintaining HIV care during the COVID-19 pandemic. Thelacent. 2020; doi: https://doi.org/https://doi.org/10.1016/S2352-3018(20)30105-3.

15.

Gralinski LE, Baric RS. Molecular pathology of emerging coronavirus infections. J Pathol. 2015;235(2):185–95.PubMedCrossRef

16.

Ogimi C, Waghmare AA, Kuypers JM, Xie H, Yeung CC, Leisenring WM, et al. Clinical significance of human coronavirus in Bronchoalveolar lavage samples from hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2017;64(11):1532–9.PubMedCrossRef

17.

Ogimi C, Englund JA, Bradford MC, Qin X, Boeckh M, Waghmare A. Characteristics and outcomes of coronavirus infection in children: the role of viral factors and an Immunocompromised state. J Pediatric Infect Dis Soc. 2019;8(1):21–8.PubMedCrossRef

18.

Diedrich CR, Flynn JL. HIV-1/mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis? Infect Immun. 2011;79(4):1407–17.PubMedPubMedCentralCrossRef

19.

Geldmacher C, Zumla A, Hoelscher M. Interaction between HIV and mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis. Curr Opin HIV AIDS. 2012;7(3):268–75.PubMed

20.

Ahmed A, Rakshit S, Vyakarnam A. HIV-TB co-infection: mechanisms that drive reactivation of mycobacterium tuberculosis in HIV infection. Oral Dis. 2016;22(Suppl 1):53–60.PubMedCrossRef

21.

Esmail H, Riou C, Bruyn ED, Lai RP, Harley YXR, Meintjes G, et al. The immune response to mycobacterium tuberculosis in HIV-1-Coinfected persons. Annu Rev Immunol. 2018;36:603–38.PubMedCrossRef

22.

World Health Organization. Global research on coronavirus disease (COVID-19). 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov. Accessed 07 May 2020.

23.

Nordic Cochrane Centre The Cochrane Collaboration. Review Manager (RevMan) [Computer program] Version Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.

24.

Suurmond R, van Rhee, H, Hak T introduction, comparison and validation of meta-essentials: A free and simple tool for meta-analysis [computer program]. Research synthesis methods. Vol. 8, Iss 4, 537–553, 2017. https://doi.org/https://doi.org/10.1002/jrsm.1260.

25.

Wells GA, B Shea, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 29 July 2020.

26.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.PubMedPubMedCentralCrossRef

27.

Del AJ, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, et al. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy: A Cohort Study. Ann Intern Med 2020; https://doi.org/https://doi.org/10.7326/M20-3689.

28.

Chen TL, Dai Z, Mo P, Li X, Ma Z, Song S, et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study. J Gerontol A Biol Sci Med Sci. 2020;20:1–8.

29.

Liu W, Fontanet A, Zhang PH, Zhan L, Xin ZT, Tang F, et al. Pulmonary tuberculosis and SARS, China. Emerg Infect Dis. 2006;12(4):707–9.PubMedPubMedCentralCrossRef

30.

Low JG, Lee CC, Leo YS. Severe acute respiratory syndrome and pulmonary tuberculosis. Clin Infect Dis. 2004;38(12):e123–5.PubMedCrossRef

31.

Wong ATY, Tsang OTY, Wong KH, Wong MYF, Lim WL, Zheng BJ, et al. Coronavirus infection in an AIDS patient. AIDS. 2004;18(5):829–30.PubMedCrossRef

32.

Alfaraj SH, Al-Tawfiq JA, Altuwaijri TA, Memish ZA. Middle East respiratory syndrome coronavirus and pulmonary tuberculosis coinfection: implications for infection control. Intervirology. 2017;60(1–2):53–5.PubMedCrossRef

33.

Singh A, Gupta A, Das K. Severe Acute Respiratory Syndrome Coronavirus-2 and Pulmonary Tuberculosis Coinfection: Double Trouble. Res Square. 2020. https://doi.org/10.21203/rs.3.rs-22464/v1.

34.

He G, Wu J, Shi J, Dai J, Gamber M, Jiang X, et al. COVID-19 in tuberculosis patients: a report of three cases. J Med Virol. 2020. https://doi.org/10.1002/jmv.25943.

35.

Cutler T, Scales D, Levine W, Schluger N, O'Donnell M. A Novel Viral Epidemic Collides with an Ancient Scourge: COVID-19 Associated with Tuberculosis. Am J Respir Crit Care Med 2020; https://www.atsjournals.org/doi/pdf/https://doi.org/10.1164/rccm.202003-0828IM.

36.

Çınar OE, Sayınalp B, Karakulak EA, Karataş AA, Velet M, İnkaya AÇ, et al. Convalescent (immune) plasma treatment in a myelodysplastic covid-19 patient with disseminated tuberculosis. Transfus Apher Sci 2020; https://doi.org/https://doi.org/10.1016/j.transci.2020.102821:102821.

37.

Faqihi F, Alharthy A, Noor AlFateh BA, Balahmar A, Karakitsos D. COVID-19 in a patient with active tuberculosis: A rare case-report. Respir Med Case Rep. 2020;31:101146.PubMedPubMedCentral

38.

Liu Y, Bi L, Chen Y, Wang Y, Fleming J, Yu Y. Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. MedRxiv BioRxiv 2020; doi: https://doi.org/https://doi.org/10.1101/2020.03.10.20033795.

39.

Tham SM, Lim WY, Lee CK, Loh J, Premkumar A, Yan B, et al. Four patients with COVID-19 and tuberculosis, Singapore, April–may 2020. Emerg Infect Dis. 2020. https://doi.org/10.3201/eid2611.202752.

40.

Stochino C, Villa S, Zucchi P, Parravicini P, Gori A, Raviglione MC. Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. Eur Respir J. 2020. https://doi.org/10.1183/13993003.01708-2020.

41.

Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55:2000524.PubMedPubMedCentralCrossRef

42.

Davies M. HIV and risk of COVID-19 death: a population cohort study from the Western Cape Province, South Africa 2020. https://www.medrxiv.org/content/10.1101/2020.07.02.20145185v2. Accessed 29 July 2020.

43.

Karla SL, Haw NJL, Uy J. Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19 2020. https://www.medrxiv.org/content/10.1101/2020.07.22.20154575v2. Accessed 29 July 2020.

44.

Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Eur Acad Allergy Clin Immunol 2020; https://doi.org/https://doi.org/10.1111/all.14238.

45.

Zhang Y, Deng A, Hu T, Chen X, Zhuang Y, Tan X, Zheng H, Sun L, Li Y, Zhong H, He J, Song T, Kang M. Clinical outcome and influencing factors of new cases of coronavirus pneumonia in Guangdong province. Chin J Epidemiol. 2020;41:E057.

46.

Zhang H, Yuan Y. Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients with Moderate to Severe COVID −19. https://clinicaltrials.gov/ct2/show/NCT04338802. Accessed 15 May 2020.

47.

Motta I, Centis R, D’Ambrosio L, García-García J, Goletti D, Gualano G, et al. Tuberculosis, COVID-19 and migrants: preliminary analysis of deaths occurring in 69 patients from two cohorts. Pulmonology. 2020; https://doi.org/https://doi.org/10.1016/j.pulmoe.2020.05.002.

48.

Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–8.PubMedPubMedCentralCrossRef

49.

Liu C, Yu Y, Fleming J, Wang T, Shen S, Wang Y, et al. Severe COVID-19 cases with a history of active or latent tuberculosis. Int J Tuberc Lung Dis 2020;http://dx.doi.org/https://doi.org/10.5588/ijld.20.0163.

50.

Covid, C.D.C. and Team R. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-march 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343–6.CrossRef

51.

Shiau S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The burden of COVID-19 in people living with HIV: a syndemic perspective. AIDS Behav. 2020;24:2244–9.PubMedCrossRefPubMedCentral

52.

Centers for Disease Control and Prevention. HIV Continuum of Care, U.S., 2014, Overall and by Age, Race/Ethnicity, Transmission Route and Sex. 2017 https://www.cdc.gov/nchhstp/newsroom/2017/HIV-Continuum-of-Care.html.. Accessed 04 Aug 2020.

53.

Hong KH, Lee SW, Kim TS, Huh HJ, Lee J, Kim SY, et al. Guidelines for laboratory diagnosis of coronavirus disease 2019 (COVID-19) in Korea. Ann Lab Med. 2020;40(5):351–60.PubMedPubMedCentralCrossRef

54.

Piatek AS, Van CM, Alexander H, Coggin WL, Rehr M, Van KS, et al. GeneXpert for TB diagnosis: planned and purposeful implementation. Glob Health Sci Pract. 2013;1(1):18–23.PubMedPubMedCentralCrossRef

55.

World Health Organization. Automated real-time DNA amplification test for rapid and simultaneous detection of TB and rifampicin resistance. 2016. https://www.who.int/tb/publications/factsheet_xpert.pdf?ua=1. Accessed 15 May 2020.

56.

Cattamanchi A, Ssewenyana I, Nabatanzi R, Miller CR, Den BS, Davis JL, et al. Bronchoalveolar lavage enzyme-linked immunospot for diagnosis of smear-negative tuberculosis in HIV-infected patients. PLoS One. 2012;7(6).

57.

World Health Organization. Latent tuberculosis infection Updated and consolidated guidelines for programmatic management. 2018. https://www.who.int/tb/publications/2018/latent-tuberculosis-infection/en/. Accessed 04 Aug 2020.

58.

Savarino A. Expanding the frontiers of existing antiviral drugs: possible effects of HIV-1 protease inhibitors against SARS and avian influenza. J Clin Virol. 2005;34(3):170–8.PubMedPubMedCentralCrossRef

59.

Baden LR, Rubin EJ. Covid-19 - the search for effective therapy. N Engl J Med. 2020;382(19):1851–2.PubMedCrossRef

60.

Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222.PubMedPubMedCentralCrossRef

61.

Ford N, Vitoria M, Rangaraj A, Norris SL, Calmy A, Doherty M. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS, or COVID-19: initial assessment. J Int AIDS Soc. 2020. https://doi.org/10.1002/:jia2.25489.

62.

Acosta EP, Kendall MA, Gerber JG, Alston-Smith B, Koletar SL, Zolopa AR, et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother. 2007;51(9):3104–10.PubMedPubMedCentralCrossRef

63.

Karanja JK, Kiboi NG, Nebere SN, HO A. Highly active antiretroviral therapy and anti-tuberculosis drug interactions with associated clinical implications: A review. J Drug Metab Toxicol. 2016;7(207):2.

64.

National Institute of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. From NIH website 2020. https://www.covid19treatmentguidelines.nih.gov/. Accessed 15 May 2020.

65.

Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.PubMedPubMedCentralCrossRef

66.

Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus. Int J Antimicrob Agents. 2020;55(3):105923.PubMedPubMedCentralCrossRef

67.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; https://doi.org/https://doi.org/10.1093/cid/ciaa237.

68.

Tobaiqy M, Qashqary M, Al-Dahery S, Mujallad A, Hershan AA, Kamal MA, et al. Therapeutic management of COVID-19 patients: A systematic review. Inf Prev Pract 2020; https://doi.org/https://doi.org/10.1016/j.infpip.2020.100061.

69.

Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. Can Med Assoc J. 2020;192(17):E450–3.CrossRef

70.

Sousa M, Pozniak A, Boffito M. Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother. 2008;62(5):872–8.PubMedCrossRef

71.

Marquez B, Van Bambeke F. ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. Curr Drug Targets. 2011;12(5):600–20.PubMedCrossRef

72.

Strydom N, Gupta SV, Fox WS, Via LE, Bang H, Lee M, et al. Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization. PLoS Med. 2019;16(4):e1002773.PubMedPubMedCentralCrossRef

73.

Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Res Treat 2011 2011; https://doi.org/https://doi.org/10.1155/2011/562790.

74.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–9.PubMedCrossRef

75.

Alhazzani W, Møller Morten H, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020;48:854–87.CrossRef

Title: Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence
Authors: Jacques L. Tamuzi
Birhanu T. Ayele
Constance S. Shumba
Olatunji O. Adetokunboh
Jeannine Uwimana-Nicol
Zelalem T. Haile
Joseph Inugu
Peter S. Nyasulu
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Tuberculosis
Tuberculosis
Rifampicin
Severe Acute Respiratory Syndrome Coronavirus
SARS-CoV-2
Middle Eastern Respiratory Syndrome
Human Immunodeficiency Virus
COVID-19
Published in: BMC Infectious Diseases / Issue 1/2020
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-020-05450-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Reduced bacterial contamination rates detected on silicone tourniquets compared to conventional tourniquets in clinical routine

Validation of the T86I mutation in the gyrA gene as a highly reliable real time PCR target to detect Fluoroquinolone-resistant Campylobacter jejuni

Measles and mumps outbreaks in Lebanon: trends and links

Unusual presentation of fatal disseminated varicella zoster virus infection in a patient with lupus nephritis: a case report

Delay in treatment initiation and its association with clinical severity and infectiousness among new adult pulmonary tuberculosis patients in Tigray, northern Ethiopia

Risk factors for mortality in hospitalized patients with COVID-19 at the start of the pandemic in Belgium: a retrospective cohort study

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage